Announcements Trials
Browse Landscape

Phase

Phase 1/2 2Phase 1 2

Status

Terminated 4Completed 2Active not recruiting 2Withdrawn 1

Sponsor Class

OTHER 3INDUSTRY 1

Study Type

Interventional 4

Sponsor

Cancer Type

Other hematologic neoplasm 31Myeloid 11Lymphoid 4Dermatologic 4Gastrointestinal 3Thoracic 2Other solid neoplasm 2Genitourinary 2Classical hematology 2Breast 2Tumor-Agnostic 1Head & Neck 1Gynecologic 1CNS 1

Conditions

Melanoma 4Neoplasm Metastasis 1Carcinoma, Renal Cell 1Carcinoma, Non-Small-Cell Lung 1

Interventions

pembrolizumab 58Cyclophosphamide 53Ipilimumab 52Nivolumab 44aldesleukin 35Interleukin-2 26fludarabine phosphate 22fludarabine 21Vemurafenib 20Temozolomide 19Radiotherapy 18dabrafenib 15trametinib 12Radiosurgery 11CTLA-4 Antigen 11Filgrastim 10Dacarbazine 10spartalizumab 9cobimetinib 9binimetinib 9atezolizumab 9Biopsy 9poly ICLC 8Paclitaxel 8Antilymphocyte Serum 8encorafenib 7avelumab 7Rituximab 7Introns 7romidepsin 6

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Terminated × Decitabine × Dermatologic × Clear all
NCT02608268 2023-12-06

Phase I-Ib/II Study of MBG453 as Single Agent and in Combination With PDR001 in Patients With Advanced Malignancies

Novartis

Phase 1/2 Terminated
252 enrolled 67 charts
DermatologicGenitourinaryThoracic

Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Melanoma

NCT00791271 2018-11-09

Parallel Phase I/II Trial of Decitabine and Peg-Interferon in Melanoma: Phase I Portion

M.D. Anderson Cancer Center

Phase 1 Terminated
17 enrolled
Dermatologic

Melanoma

NCT01876641 2018-09-19

ML28604

University of Iowa

Phase 1 Terminated
18 enrolled
Dermatologic

Melanoma

NCT00925132 2017-07-02

Treatment of Resistant Metastatic Melanoma Using Decitabine, Temozolomide and Panobinostat

University of Iowa

Phase 1/2 Terminated
39 enrolled 8 charts
Dermatologic

Melanoma, Neoplasm Metastasis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡